Association Between Individualized Estimated Glomerular Filtration Rate and Cumulative Cisplatin Dose in Head and Neck Cancer

<h3>Background/Aim:</h3> In concurrent chemoradiotherapy (CCRT) for head and neck cancer, achieving a cumulative cisplatin dose of ≥200 mg/m<sup>2</sup> is associated with improved outcomes. However, treatment modification due to toxicity remains a challenge. As cisplatin is primarily excreted by the kidneys, assessment of renal function is important. This study investigated the association between individualized estimated glomerular filtration rate (eGFR) and cumulative cisplatin dose in patients with head and neck cancer undergoing CCRT. <h3>Patients and Methods:</h3> This retrospective study included patients with head and neck cancer who received CCRT with cisplatin (80 mg/m<sup>2</sup> every three weeks for three cycles) at Niigata University Medical and Dental Hospital between April 2015 and March 2024. The primary endpoint was the cumulative cisplatin dose. Renal function was assessed using individualized eGFR, and patients were categorized into ≥200 mg/m<sup>2</sup> and &lt;200 mg/m<sup>2</sup> groups. Logistic regression analysis was performed to identify factors associated with a cumulative cisplatin dose of &lt;200 mg/m<sup>2</sup>. <h3>Results:</h3> Among 158 patients, 27 (17%) received a cumulative cisplatin dose of &lt;200 mg/m<sup>2</sup>. Although all patients had a Cockcroft–Gault creatinine clearance (CGCCr) ≥60 ml/min, 8 (5%) had an individualized eGFR &lt;60 ml/min. The proportion of patients with an eGFR &lt;60 ml/min was significantly higher in the &lt;200 mg/m<sup>2</sup> group (15% <i>vs</i>. 3%, <i>p</i>=0.03). In the multivariate analysis, eGFR &lt;60 ml/min was associated with a cumulative cisplatin dose &lt;200 mg/m<sup>2</sup> (adjusted odds ratio=4.66; 95% confidence interval=1.06-20.5; <i>p</i>=0.041). <h3>Conclusion:</h3> In patients with head and neck cancer undergoing cisplatin-based CCRT, individualized eGFR &lt;60 ml/min was associated with a reduced cumulative cisplatin dose despite adequate CGCCr. Assessment using eGFR may improve pre-treatment evaluation of renal function in this setting.

Authors

Institutions

Publication Details

Journal
Anticancer Research
Published
2026-06-29
DOI
https://doi.org/10.21873/anticanres.18265
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association Between Individualized Estimated Glomerular Filtration Rate and Cumulative Cisplatin Dose in Head and Neck Cancer

Yoshitomi Kanemitsu, Akira TOYAMA, NAOTO HOSHINO, KENSUKE YOSHIDA et al.
Anticancer Research
Head and Neck Cancer Studies
article

Association Between Individualized Estimated Glomerular Filtration Rate and Cumulative Cisplatin Dose in Head and Neck Cancer

Yoshitomi Kanemitsu, Akira TOYAMA, NAOTO HOSHINO, KENSUKE YOSHIDA, MUNETOSHI SUGIURA
article en

Abstract

<h3>Background/Aim:</h3> In concurrent chemoradiotherapy (CCRT) for head and neck cancer, achieving a cumulative cisplatin dose of ≥200 mg/m<sup>2</sup> is associated with improved outcomes. However, treatment modification due to toxicity remains a challenge. As cisplatin is primarily excreted by the kidneys, assessment of renal function is important. This study investigated the association between individualized estimated glomerular filtration rate (eGFR) and cumulative cisplatin dose in patients with head and neck cancer undergoing CCRT. <h3>Patients and Methods:</h3> This retrospective study included patients with head and neck cancer who received CCRT with cisplatin (80 mg/m<sup>2</sup> every three weeks for three cycles) at Niigata University Medical and Dental Hospital between April 2015 and March 2024. The primary endpoint was the cumulative cisplatin dose. Renal function was assessed using individualized eGFR, and patients were categorized into ≥200 mg/m<sup>2</sup> and &lt;200 mg/m<sup>2</sup> groups. Logistic regression analysis was performed to identify factors associated with a cumulative cisplatin dose of &lt;200 mg/m<sup>2</sup>. <h3>Results:</h3> Among 158 patients, 27 (17%) received a cumulative cisplatin dose of &lt;200 mg/m<sup>2</sup>. Although all patients had a Cockcroft–Gault creatinine clearance (CGCCr) ≥60 ml/min, 8 (5%) had an individualized eGFR &lt;60 ml/min. The proportion of patients with an eGFR &lt;60 ml/min was significantly higher in the &lt;200 mg/m<sup>2</sup> group (15% <i>vs</i>. 3%, <i>p</i>=0.03). In the multivariate analysis, eGFR &lt;60 ml/min was associated with a cumulative cisplatin dose &lt;200 mg/m<sup>2</sup> (adjusted odds ratio=4.66; 95% confidence interval=1.06-20.5; <i>p</i>=0.041). <h3>Conclusion:</h3> In patients with head and neck cancer undergoing cisplatin-based CCRT, individualized eGFR &lt;60 ml/min was associated with a reduced cumulative cisplatin dose despite adequate CGCCr. Assessment using eGFR may improve pre-treatment evaluation of renal function in this setting.

Anticancer ResearchVol. 46(7)
Tokyo University of Pharmacy and Life Sciences (JP), Niigata University Medical and Dental Hospital (JP)
Good health and well-being
Openalex Percentile: Top 7%
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.